Marinus Pharmaceuticals Inc (MRNS):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Marinus Pharmaceuticals Inc (MRNS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8011
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:50
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Marinus Pharmaceuticals Inc (Marinus) is a clinical stage biopharmaceutical company that manufactures and commercializes therapeutics for the treatment of epilepsy, neuropsychiatric disorders and others diseases. The company’s pipeline product comprise ganaxolone is a CNS-selective GABAA modulator, which has being developed in three different dose forms such as IV, capsule and liquid that is intended to maximize therapeutic reach to adult and pediatric patients in both acute and chronic care settings. Its Ganaxolone product has being evaluated in clinical trials for the treatment of pediatric genetic orphan epilepsies, behaviours in fragile x syndrome, and status epilepticus. Marinus is headquartered in Radnor, Pennsylvania, the US.

Marinus Pharmaceuticals Inc (MRNS) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Marinus Pharma Raises US$21 Million In Series C Financing 11
Marinus Pharmaceuticals Raises USD11.43 in Venture Financing 13
Marinus Pharma Raises USD21.8 Million in Venture Financing 14
Licensing Agreements 15
Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 15
CyDex Pharma Enters into Licensing Agreement with Marinus Pharma 16
Equity Offering 17
Marinus Pharma Plans to Raise up to USD200 Million in Public Offering of Securities 17
Marinus Pharma Raises USD40.3 Million in Public Offering of Shares 18
Marinus Pharma Raises USD30 Million in Public Offering of Shares 20
Marinus Pharma Files Registration Statement for Public Offering of Shares for up to USD35 Million 21
Marinus Pharma Completes IPO 22
Marinus Pharmaceuticals Inc – Key Competitors 24
Marinus Pharmaceuticals Inc – Key Employees 25
Marinus Pharmaceuticals Inc – Locations And Subsidiaries 26
Head Office 26
Recent Developments 27
Financial Announcements 27
Aug 02, 2018: Marinus Pharmaceuticals Provides Business Update and Second Quarter 2018 Financial Results 27
May 02, 2018: Marinus Pharmaceuticals Provides Business Update and First Quarter 2018 Financial Results 29
Mar 06, 2018: Marinus Pharmaceuticals Provides Business Update and 2017 Financial Results 30
Oct 31, 2017: Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2017 Financial Results 32
Aug 01, 2017: Marinus Pharmaceuticals Reports Second Quarter 2017 Financial Results 34
Mar 13, 2017: Marinus Pharmaceuticals Provides Business Update and 2016 Financial Results 35
Corporate Communications 36
Apr 11, 2017: Dr. Lorianne K. Masuoka Joins Marinus Pharmaceuticals as Chief Medical Officer 36
Feb 01, 2017: Marinus Appoints Michael R. Dougherty to its Board of Directors 37
Product Approvals 38
Jun 29, 2017: FDA Grants Orphan Drug Designation for Ganaxolone in CDKL5 Disorder 38
Jan 03, 2017: Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone to Treat Fragile X Syndrome 39
Clinical Trials 40
Sep 11, 2017: Marinus Announces Successful Clinical Trial Results and Declares CDKL5 Disorder Its Lead Pediatric Orphan Epilepsy Program for Ganaxolone 40
Aug 01, 2017: Marinus Pharmaceuticals Announces Update on Ganaxolone 42
Jun 27, 2017: Marinus Pharmaceuticals Launches the Ganaxolone Clinical Program in Patients with Postpartum Depression 43
Apr 18, 2017: Marinus to present Ganaxolone DATA at American academy of neurology annual meeting 44
Apr 10, 2017: Ganaxolone IV Clinical Data Presented at Leading International Status Epilepticus Medical Conference 45
Feb 14, 2017: Ganaxolone Reduces Seizures and Improves Behaviors in Angelman Syndrome Preclinical Model 46
Jan 23, 2017: Marinus Announces Positive Preliminary Data From Children With CDKL5 Genetic Disorder 47
Jan 05, 2017: Marinus Provides Business Outlook for 2017 48
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Marinus Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Marinus Pharma Raises US$21 Million In Series C Financing 11
Marinus Pharmaceuticals Raises USD11.43 in Venture Financing 13
Marinus Pharma Raises USD21.8 Million in Venture Financing 14
Marinus Pharma Enters into Licensing Agreement with Ligand Pharma 15
CyDex Pharma Enters into Licensing Agreement with Marinus Pharma 16
Marinus Pharma Plans to Raise up to USD200 Million in Public Offering of Securities 17
Marinus Pharma Raises USD40.3 Million in Public Offering of Shares 18
Marinus Pharma Raises USD30 Million in Public Offering of Shares 20
Marinus Pharma Files Registration Statement for Public Offering of Shares for up to USD35 Million 21
Marinus Pharma Completes IPO 22
Marinus Pharmaceuticals Inc, Key Competitors 24
Marinus Pharmaceuticals Inc, Key Employees 25

List of Figures
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Marinus Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Marinus Pharmaceuticals Inc (MRNS):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Vaxil Bio Ltd (VXL):製薬・医療:M&Aディール及び事業提携情報
    Summary Vaxil Bio Ltd (Vaxil Bio), formerly Emerge Resources Corp, is a drug development company that develops immunotherapy platform. The company’s immunptherapy pipeline products include antigen specific immunotherapies, signal peptide specific antibodies and anti-infectives. It develops Vaxhit te …
  • ALK-Abello AS (ALK B):製薬・医療:M&Aディール及び事業提携情報
    Summary ALK-Abello AS (ALK), a subsidiary of The Lundbeck Foundation discovers, develops and commercializes immunotherapies for allergy prevention and treatment. It markets diagnostics and other services to allergy clinics. The company's allergy immunotherapy product portfolio includes tablet-based …
  • Hornbeck Offshore Services Inc (HOS):石油・ガス:M&Aディール及び事業提携情報
    Summary Hornbeck Offshore Services Inc (HOS) is a provider of marine services. The company offers marine transportation, subsea installation and accommodation support services to exploration and production, oilfield service, offshore construction and the US military customers. It supplies vessels, t …
  • Conatus Pharmaceuticals Inc (CNAT):企業の財務・戦略的SWOT分析
    Summary Conatus Pharmaceuticals Inc (Conatus) is a biotechnology company that develops and commercializes novel medicines for the treatment of liver diseases. The company’s lead pipeline candidate includes emricasan, an orally active pan-caspase protease inhibitor which is designed to reduce the act …
  • Hikal Ltd (HIKAL):企業の財務・戦略的SWOT分析
    Summary Hikal Ltd (Hikal) is a pharmaceutical company that provides custom manufacturing; active ingredients and intermediates. The company provides product portfolio such as antiepileptic, antihistamine, antipsychotic and antilipemic, among others. It offers services such as custom synthesis, contr …
  • SEAKR Engineering, Inc.:企業の戦略・SWOT・財務分析
    SEAKR Engineering, Inc. - Strategy, SWOT and Corporate Finance Report Summary SEAKR Engineering, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • The Co-Operators Group Limited:企業の戦略的SWOT分析
    The Co-Operators Group Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major prod …
  • RPG Cables Limited:企業の戦略・SWOT・財務情報
    RPG Cables Limited - Strategy, SWOT and Corporate Finance Report Summary RPG Cables Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Ardena Holding NV:製薬・医療:M&Aディール及び事業提携情報
    Summary Ardena Holding NV (Ardena) is a contract development and manufacturing organization. The company offers solid-state chemistry services including polymorph, salt, and co-crystal screening; bio-analytical and formulation development; early-phase clinical supply manufacturing; clinical logistic …
  • CK Infrastructure Holdings Ltd (1038):電力:M&Aディール及び事業提携情報
    Summary CK Infrastructure Holdings Limited (CKI), a subsidiary of CK Hutchison Holdings Limited, is an infrastructure investment company. It holds diversified investment interests across various sectors including energy, rail transportation, water, waste management, and other infrastructure related …
  • Myers Industries Inc (MYE):企業の財務・戦略的SWOT分析
    Summary Myers Industries Inc (Myers) is a chemical company that manufactures and distributes plastic and rubber products. The company offers plastic storage containers, rubber tire repair products, custom plastic and rubber products, tire balancers and tire retread products. It also provides materia …
  • Oncgnostics GmbH:企業の製品パイプライン分析
    Summary Oncgnostics GmbH (Oncgnostics) is an in-vitro diagnostic company that offers development of in-vitro diagnostic tests for the therapeutics area of cancer. The company offers pipeline products such as GynTect technology a system based on the detection of epigenetic biomarkers mainly in the me …
  • Abg Sundal Collier Holding Asa:企業の戦略・SWOT・財務分析
    Abg Sundal Collier Holding Asa - Strategy, SWOT and Corporate Finance Report Summary Abg Sundal Collier Holding Asa - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Covestro AG (1COV):企業の財務・戦略的SWOT分析
    Covestro AG (1COV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Abu Dhabi National Energy Co (TAQA):企業の財務・戦略的SWOT分析
    Abu Dhabi National Energy Co (TAQA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Pearson plc:企業の戦略・SWOT・財務情報
    Pearson plc - Strategy, SWOT and Corporate Finance Report Summary Pearson plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • BOC Hong Kong (Holdings) Ltd:戦略・SWOT・企業財務分析
    BOC Hong Kong (Holdings) Ltd - Strategy, SWOT and Corporate Finance Report Summary BOC Hong Kong (Holdings) Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Chongqing Lummy Pharmaceutical Co Ltd (300006):製薬・医療:M&Aディール及び事業提携情報
    Summary Chongqing Lummy Pharmaceutical Co Ltd (Lummy) is a pharmaceutical company that provides pharmaceutical ingredients and drugs and related products. The company’s products include antibacterial drugs, antifungal drugs, tumor drugs, immune system agents, blood system agents, cardiovascular syst …
  • The Dun & Bradstreet Corporation:企業の戦略・SWOT・財務情報
    The Dun & Bradstreet Corporation - Strategy, SWOT and Corporate Finance Report Summary The Dun & Bradstreet Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Soventix GmbH:電力:M&Aディール及び事業提携情報
    Summary Soventix GmbH (Soventix) is a renewable energy company that develops and constructs solar plants and hybrid plants. The company’s services include planning and development, financing and management, and service and operations. Its projects include Essa Public School, 40 Holtby, Seaboard, Res …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆